Evaxion’s EVX-01 Phase 2 Trial Shows 92% Of Melanoma Patients Still Responding At Two Years With No Relapses, And All Responses Maintained At Three Years Without Progression

Loading news article.

Evaxion’s EVX-01 Phase 2 Trial Shows 92% Of Melanoma Patients Still Responding At Two Years With No Relapses, And All Responses Maintained At Three Years Without Progression | WAPE

Evaxion’s EVX-01 Phase 2 Trial Shows 92% Of Melanoma Patients Still Responding At Two Years With No Relapses, And All Responses Maintained At Three Years Without Progression

Article summary

Related companies

Analyzed by WAPE AI.

Comments —